AAAAAA
Results: 26-46/46
Authors:
Meric, JB
Faivre, S
Monnerat, C
Vago, NA
Le Chevalier, T
Armand, JP
Raymond, E
Citation: Jb. Meric et al., ZD 1839 "Iressa", B CANCER, 87(12), 2000, pp. 873-876
Authors:
Hasbini, A
Raymond, E
Cvitkovic, E
Eschwege, F
Armand, JP
Citation: A. Hasbini et al., Carcinomas of the nasopharynx, B CANCER, 2000, pp. 21-26
Authors:
Soria, JC
Gauthier, LR
Raymond, E
Granotier, C
Morat, L
Armand, JP
Boussin, FD
Sabatier, L
Citation: Jc. Soria et al., Molecular detection of telomerase-positive circulating epithelial cells inmetastatic breast cancer patients, CLIN CANC R, 5(5), 1999, pp. 971-975
Authors:
Zeghari-Squalli, N
Raymond, E
Cvitkovic, E
Goldwasser, F
Citation: N. Zeghari-squalli et al., Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin, CLIN CANC R, 5(5), 1999, pp. 1189-1196
Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors
Authors:
Soda, H
Raymond, E
Sharma, S
Lawrence, R
Cerna, C
Gomez, L
Schaub, R
Von Hoff, DD
Izbicka, E
Citation: H. Soda et al., Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors, ANTI-CANC D, 10(1), 1999, pp. 97-101
Authors:
Hasbini, A
Mahjoubi, R
Fandi, A
Chouaki, N
Taamma, A
Lianes, P
Cortes-Funes, H
Alonso, S
Armand, JP
Cvitkovic, E
Raymond, E
Citation: A. Hasbini et al., Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type, ANN ONCOL, 10(4), 1999, pp. 421-425
Authors:
Raymond, E
Citation: E. Raymond, Getting quantitative results - Reply, IEEE SOFTW, 16(4), 1999, pp. 14-14
Authors:
Faivre, S
Raymond, E
Woyarowski, JM
Cvitkovic, E
Citation: S. Faivre et al., Supraadditive effect of 2 ',2 '-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines, CANC CHEMOT, 44(2), 1999, pp. 117-123
Authors:
Izbicka, E
Nishioka, D
Marcell, V
Raymond, E
Davidson, KK
Lawrence, RA
Wheelhouse, RT
Hurley, LH
Wu, RS
Von Hoff, DD
Citation: E. Izbicka et al., Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos, ANTI-CAN DR, 14(4), 1999, pp. 355-365
Authors:
Mabro, M
Faivre, S
Raymond, E
Citation: M. Mabro et al., A risk-benefit assessment of amifostine in cytoprotection, DRUG SAFETY, 21(5), 1999, pp. 367-387
Authors:
Mills, JL
DerSimonian, R
Raymond, E
Morrow, JD
Roberts, LJ
Clemens, JD
Hauth, JC
Catalano, P
Sibai, B
Curet, LB
Levine, RJ
Citation: Jl. Mills et al., Prostacyclin and thromboxane changes predating clinical onset of preeclampsia - A multicenter prospective study, J AM MED A, 282(4), 1999, pp. 356-362
Authors:
Raymond, E
Dominik, R
Citation: E. Raymond et R. Dominik, Contraceptive effectiveness of two spermicides: A randomized trial, OBSTET GYN, 93(6), 1999, pp. 896-903
Authors:
Steiner, MJ
Hertz-Picciotto, I
Raymond, E
Trussell, J
Wheeless, A
Schoenbach, V
Citation: Mj. Steiner et al., Influence of cycle variability and coital frequency on the risk of pregnancy, CONTRACEPT, 60(3), 1999, pp. 137-143
Authors:
Raymond, E
Alvarado, G
Ledesma, L
Diaz, S
Bassol, S
Morales, E
Fernandez, V
Carlos, G
Citation: E. Raymond et al., Acceptability of two spermicides in five countries, CONTRACEPT, 60(1), 1999, pp. 45-50
Authors:
Izbicka, E
Wheelhouse, RT
Raymond, E
Davidson, KK
Lawrence, RA
Sun, DY
Windle, BE
Hurley, LH
Von Hoff, DD
Citation: E. Izbicka et al., Effects of cationic porphyrins as G-quadruplex interactive agents in humantumor cells, CANCER RES, 59(3), 1999, pp. 639-644
Authors:
Raymond, E
Bahdai, Z
Waters, H
Kinzie, S
Chan, WL
Blake, E
Evans, MF
Chan, D
Shaw, E
Citation: E. Raymond et al., What's new in smoking cessation: Zyban, CAN FAM PHY, 45, 1999, pp. 633-634
Authors:
Alexandre, J
Raymond, E
Armand, JP
Citation: J. Alexandre et al., Rapamycin and CCI-779, B CANCER, 86(10), 1999, pp. 808-811
Authors:
Raymond, E
Sun, D
Izbicka, E
Mangold, G
Silvas, E
Windle, B
Sharma, S
Soda, H
Laurence, R
Davidson, K
Von Hoff, DD
Citation: E. Raymond et al., A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay, BR J CANC, 80(9), 1999, pp. 1332-1341
Authors:
Andre, T
Louvet, C
Raymond, E
Tournigand, C
de Gramont, A
Citation: T. Andre et al., Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen, ANN ONCOL, 9(11), 1998, pp. 1251-1253
Authors:
Boige, V
Raymond, E
Armand, JP
Citation: V. Boige et al., Irinotecan: drug schedule, research of combinations, and phase I experiences, B CANCER, 1998, pp. 26-32
Authors:
Soria, JC
Raymond, E
Citation: Jc. Soria et E. Raymond, Biology and cancer: What's new in 1998? Telomerase(s), telomers and cancer: A continuing saga, EUROCANCER 98, 1998, pp. 141-142